Liquidia CORP Form 4 insider transactions
NASDAQ
LQDA
Liquidia CORPLiquidia Corp Director Paul B. Manning reported a change in the form of his beneficial ownership, withdrawing 55,116 shares from a grantor retained annuity trust.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Accounting Officer, Dana Boyle, sold 1,580 shares of common stock at $41.65 per share to cover tax liabilities from restricted stock unit settlements.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Business Officer, Jason Adair, sold 688 shares of common stock at $41.65 per share to cover tax liabilities from restricted stock unit settlements.
NASDAQ
LQDA
Liquidia CORPLiquidia Corporation's Chief Business Officer, Jason Adair, was granted 27,683 Restricted Stock Units and 41,525 Performance Stock Units on January 16, 2026.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Accounting Officer, Dana Boyle, received grants of 23,728 Restricted Stock Units and 35,592 Performance Stock Units.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's CEO and Director, Roger Jeffs, reported the acquisition of 115,344 Restricted Stock Units and 173,016 Performance Stock Units.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's CFO and COO, Michael Kaseta, was granted 59,320 Restricted Stock Units and 88,980 Performance Stock Units on January 16, 2026.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Development Officer, Sanjeev Khindri, was granted 34,274 Restricted Stock Units, increasing his total unvested RSU holdings to 71,266.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Human Resource Officer, Sarah Krepp, received grants of Restricted Stock Units and Performance Stock Units on January 16, 2026.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Commercial Officer, Scott Moomaw, received substantial equity awards, including Restricted Stock Units and Performance Stock Units, on January 16, 2026.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Medical Officer, Rajeev Saggar, received significant equity grants including Restricted Stock Units and Performance Stock Units, aligning his incentives with future company performance.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's General Counsel, Russell Schundler, increased his beneficial ownership through new grants of restricted and performance stock units.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Human Resource Officer, Sarah Krepp, sold 13,165 shares of common stock for $37.43 per share to cover tax obligations following the vesting of performance and restricted stock units.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Commercial Officer, Scott Moomaw, sold 20,533 shares of common stock at $37.43 per share to cover tax liabilities from vested equity awards.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's CFO and COO, Michael Kaseta, reported the acquisition of common stock from vested performance stock units and the subsequent sale of shares to cover tax liabilities.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Business Officer, Jason Adair, executed a planned sale of 13,548 common shares to cover tax liabilities from equity award vesting.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's General Counsel, Russell Schundler, reported the acquisition of common stock from vested performance stock units and the subsequent sale of shares to cover tax liabilities.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's CEO, Roger Jeffs, reported the sale of 66,610 common shares at $37.43 to cover tax liabilities from vested equity awards, executed under a pre-arranged 10b5-1 plan.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Accounting Officer, Dana Boyle, converted performance stock units into common stock and subsequently sold a portion to cover tax obligations.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Medical Officer, Rajeev Saggar, reported the sale of 21,142 common shares at $37.43 to cover tax liabilities from vested equity awards, as part of a pre-arranged 10b5-1 plan.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's General Counsel, Russell Schundler, reported the acquisition of common stock from RSU conversion and subsequent sale of shares to cover tax obligations.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Human Resource Officer, Sarah Krepp, sold 221 shares of common stock at $32.19 to cover tax liabilities from restricted stock unit settlements.
NASDAQ
LQDA
Liquidia CORPLiquidia Corporation's CFO and COO, Michael Kaseta, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, executed under a Rule 10b5-1 plan.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Accounting Officer, Dana Boyle, sold 303 shares of common stock at $32.19 per share to cover tax liabilities from RSU settlements.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Business Officer, Jason Adair, reported the acquisition of common stock from RSU vesting and a subsequent sale to cover tax obligations.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Commercial Officer, Scott Moomaw, acquired shares from RSU vesting and subsequently sold a portion to cover tax liabilities.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Business Officer, Jason Adair, exercised stock options and subsequently sold 35,656 shares of common stock for approximately $1.07 million.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Accounting Officer, Dana Boyle, sold a total of 29,004 shares of common stock in pre-planned transactions on November 7, 2025.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Medical Officer, Rajeev Saggar, sold 71,381 shares of common stock for $27 per share in a pre-arranged transaction.
NASDAQ
LQDA
Liquidia CORPLiquidia Corp's Chief Business Officer, Jason Adair, sold 692 shares of common stock to cover tax liabilities from restricted stock unit vesting, as per a pre-arranged 10b5-1 plan.